Enhanced pathologic tumor response with two cycles of neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV-negative head and neck squamous cell carcinoma (HNSCC). This is an ASCO ...
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma E3311 is a phase II randomized trial of reduced- or standard-dose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results